<DOC>
	<DOCNO>NCT01272310</DOCNO>
	<brief_summary>The study aim investigate safety , tolerability efficacy fix dose combination therapy : Hydroxychloroquine ( HCQ ) , Pegylated Interferon Alpha-2a ( PEG-IFN alpha-2a ) Ribavirin ( RBV ) Chronic Hepatitis C Genotype 1 Infected adult subject fail respond follow course PEG-IFN RBV Therapy .</brief_summary>
	<brief_title>Clinical Trial Assess Safety Efficacy Combination Therapy : Hydroxychloroquine , Pegylated Interferon Alpha-2a Ribavirin Chronic Hepatitis C Subjects Non-responders Standard Care Therapy .</brief_title>
	<detailed_description>This phase I/II , open clinical trial ass safety , tolerability preliminary efficacy data fix dose combination therapy : HCQ , Peg-IFN alpha-2a RBV chronic hepatitis C genotype 1 infected subject fail respond follow course Peg-IFN RBV Therapy ( SoC ) . The study single center trial conduct Department Gastroenterology &amp; Hepatology , Sheba Medical Center , Tel Hashomer , Israel . Overall , thirty six ( 36 ) patient recruit . All patient enrol documented history chronic HCV disease non-responder earlier Peg-IFN base treatment last least 12 consecutive week prior study enrolment . The expected duration patient screen period prior enrollment study in-between six week ( 42 day ) 2 day prior study enrollment day visit 2 ( verification compliance inclusion/exclusion criterion include clinical laboratory result ) . Eligible patient enrol study observe twice first week study , week initiation treatment period week 2,3 week 4 , later treatment period month week 8-48 two follow visit post treatment take place week 60 72 ( allow time window ± 5 day visit ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>1 . Males females 18 70 year old . 2 . Subjects diagnose positive HCV antibody use third generation test . 3 . Subject diagnose detectable HCV RNA PCR . 4 . Liver biopsy FibroTest show METAVIR score ≥F2 and/or ≥A2 . 5 . Subject diagnose compensate liver disease . 6 . Subject nonresponder ( null partial ) prior PegIFN RBV base treatment last least 12 consecutive week . 7 . Treatment discontinue due intolerability PegIFN RBV . 8 . Subjects able comprehend give informed consent participation study . 9 . Subject willing treat commit visit . 1 . Anti HCV therapy contraindication . 2 . Subject identify relapser prior PegIFN RBV base treatment . 3 . Hypersensitivity one three drug ( HCQ , PegIFN , RBV ) . 4 . Patient Anaemia , neutropenia , thrombocytopenia , elevate bilirubin level , elevate ALT and/or AST , elevate creatinin INR great 1.5 . 5 . Concomitant liver disease hepatitis C : chronic hepatitis B , alcoholic liver disease , autoimmune hepatitis , Wilson 's disease , hemochromatosis , alpha1 antitrypsin deficiency . 6 . Decompensated cirrhosis ( Child Pugh &gt; A ) . 7 . Clinical evidence hepatocellular carcinoma . 8 . Human immunodeficiency virus coinfection . 9 . Major uncontrolled psychiatric illness . Minor situational depression allow . 10 . Active elicit drug alcohol abuse . 11 . Serious comorbid condition : heart failure , significant coronary heart disease , chronic obstructive pulmonary disease , renal insufficiency , poorly control diabetes , autoimmune disorder , malignant diseases previous 5 year . 12 . Immunosuppressive treatment include corticosteroid , 13 . Untreated uncontrolled thyroid disease . 14 . Solid transplant organ ( renal , heart , lung ) . 15 . Pregnancy unwillingness practice double contraception abstinence subject childbearing potential partner . 16 . Subject object study protocol . 17 . Concurrent participation clinical study within 30 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>Hydroxychloroquine</keyword>
	<keyword>Pegylated Interferon Alpha-2a</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Chronic Hepatitis C Genotype 1 infect adult subject</keyword>
</DOC>